[Clinical evaluation of flomoxef in children]
Related Experiment Videos
H Meguro1, O Arimasu, K Sugamata
1Department of Pediatrics, School of Medicine, Teikyo University.
Abstract:
Flomoxef (FMOX, 6315-S), a new parenteral oxacephem antibiotic, was evaluated for its safety, efficacy and pharmacokinetics in children. Twenty-six patients with bacterial infections were treated with FMOX. Clinical efficacy rate was 92% and bacteriological cure rate was 85%. Three cases of infections due to methicillin-resistant Staphylococcus aureus were cured with FMOX therapy. No severe adverse reactions or abnormalities of laboratory test data were associated with FMOX therapy, although loose stools and diarrhea occurred frequently (23%). Serum half-lives of FMOX after a single bolus injection of 9 infants and children were 0.77 +/- 0.31 hour and excretion into urine was rapid. From these experiences, FMOX appeared to be a safe and effective antibiotic when used in children with susceptible bacterial infections.
Insights
Flomoxef (FMOX) is a safe and effective parenteral oxacephem antibiotic for treating bacterial infections in children, including those caused by MRSA. It demonstrated high clinical and bacteriological cure rates with minimal adverse effects.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Context:
- Bacterial infections in children require effective and safe antibiotic treatments.
- Parenteral antibiotics are crucial for severe pediatric infections.
- Oxacephem antibiotics represent a class of beta-lactam antibiotics.
Purpose:
- To evaluate the safety, efficacy, and pharmacokinetics of Flomoxef (FMOX) in pediatric patients.
- To assess FMOX's clinical and bacteriological cure rates in children with bacterial infections.
- To determine the pharmacokinetic profile of FMOX in infants and children.
Summary:
- Flomoxef (FMOX) was administered to 26 pediatric patients with bacterial infections.
- High clinical efficacy (92%) and bacteriological cure rates (85%) were observed.
- Three cases of methicillin-resistant Staphylococcus aureus (MRSA) infections were successfully treated.
- Adverse events were generally mild, with loose stools and diarrhea being most frequent (23%).
- Rapid excretion and a serum half-life of 0.77 +/- 0.31 hours were noted in 9 pediatric subjects.
Impact:
- Flomoxef (FMOX) is a promising parenteral antibiotic for pediatric use.
- Demonstrates efficacy against susceptible bacterial pathogens, including MRSA.
- Supports the use of FMOX as a safe therapeutic option in pediatric infectious disease management.